Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition

Francesca Megiorni(Sapienza University of Rome), Carlo Dominici(Sapienza University of Rome)
Journal of Experimental & Clinical Cancer Research
October 6, 2015
10.1186/s13046-015-0228-4
Cited by 55

Related Papers

DNMT3B<i>in vitro</i>knocking-down is able to reverse embryonal rhabdomyosarcoma cell phenotype through inhibition of proliferation and induction of myogenic differentiation
|Oncotarget|2016|40
Clinical and Molecular Evidence for c-kit Receptor as a Therapeutic Target in Neuroblastic Tumors
|Clinical Cancer Research|2005|38
PARP inhibitors affect growth, survival and radiation susceptibility of human alveolar and embryonal rhabdomyosarcoma cell lines
|Journal of Cancer Research and Clinical Oncology|2018|35
DNMT3A and DNMT3B Targeting as an Effective Radiosensitizing Strategy in Embryonal Rhabdomyosarcoma
|Cells|2021|27
OTX015 Epi-Drug Exerts Antitumor Effects in Ovarian Cancer Cells by Blocking GNL3-Mediated Radioresistance Mechanisms: Cellular, Molecular and Computational Evidence
|Cancers|2021|19